Amphastar Pharmaceuticals (AMPH) Non-Current Deferred Tax Liability (2013 - 2023)

Amphastar Pharmaceuticals' Non-Current Deferred Tax Liability history runs 11 years deep, the most recent figure standing at $201000.0 for Q3 2023.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 16.94% year-over-year to $201000.0 in Q3 2023; TTM through Sep 2023 was $201000.0, a 16.94% decrease from a year earlier, with the FY2022 full-year figure at $144000.0, down 73.03% from the prior year.
• Non-Current Deferred Tax Liability held at $201000.0 in Q3 2023 per AMPH's latest filing, from $201000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $2.9 million in Q3 2021 and bottomed at $144000.0 in Q4 2022.
• The 5-year median for Non-Current Deferred Tax Liability is $748000.0 (2020), against an average of $724222.2.
• Across the five-year window, Non-Current Deferred Tax Liability jumped 252.49% in 2021 and tumbled 91.66% in 2022, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $867000.0 in 2019, then declined by 14.53% to $741000.0 in 2020, then fell by 27.94% to $534000.0 in 2021, then tumbled by 73.03% to $144000.0 in 2022, then jumped by 39.58% to $201000.0 in 2023.
• Per Business Quant, the three latest AMPH Non-Current Deferred Tax Liability figures stand at $201000.0 (Q3 2023), $201000.0 (Q2 2023), and $178000.0 (Q1 2023).